Study confirms efficacy of BLIS K12 in preventing throat infections in children

The probiotic showed a 96% reduction in the incidence of streptococcal sore throats in children

Stratum Nutrition's BLIS K12 probiotic showed a 96% reduction in the incidence of streptococcal sore throats in children, in a study recently published in Drug, Healthcare and Patient Safety.1

The multicentre study evaluated the benefits of BLIS K12 (Streptococcus salivarius) on two of the most common illnesses in children: streptococcal and viral pharyngotonsillitis.

Sixty children aged between 3–13 years with a history of recurrent throat infection, were enrolled on the study. Thirty consumed lozenges containing BLIS K12 probiotic for 90 days, with the other 30 acting as the control group.

The study also showed a reduction in viral infections (by 80%) and in the number of days with antibiotic (amoxicillin) and antipyretics use (by 30-fold and 14-fold, respectively).

The number of days that the children who took BLIS K12 were absent from school or work was also reduced from 228 to 16 days.

These findings reconfirm an earlier clinical study where BLIS K12 was shown to reduce the recurrence of otitis media and pharyngotonsillitis by around 40% and 90%, respectively. 2

References

1. Di Pierro, F., et al.(2014). Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug, Healthcare and Patient Safety 2014:6 15-20.

2. Di Pierro, F., et al. International Journal of General Medicine, 2012:5 991-997

Companies